Carlo Broos Sells 4,647 Shares of Cibus, Inc. (NASDAQ:CBUS) Stock

Cibus, Inc. (NASDAQ:CBUS) CFO Carlo Broos sold 4,647 shares of the firm’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $5.30, for a total transaction of $24,629.10. Following the completion of the sale, the chief financial officer now owns 74,197 shares of the company’s stock, valued at $393,244.10. This trade represents a 5.89 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Cibus Stock Performance

Shares of NASDAQ:CBUS opened at $4.53 on Friday. The firm has a market cap of $119.86 million, a PE ratio of -0.20 and a beta of 1.79. The firm’s 50 day simple moving average is $4.03 and its 200-day simple moving average is $8.55. Cibus, Inc. has a one year low of $2.86 and a one year high of $23.18.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. FMR LLC lifted its holdings in shares of Cibus by 16.9% in the 3rd quarter. FMR LLC now owns 3,913,279 shares of the company’s stock worth $12,757,000 after buying an additional 566,328 shares during the period. Armistice Capital LLC bought a new stake in shares of Cibus in the second quarter valued at about $5,083,000. State Street Corp lifted its stake in Cibus by 43.6% in the third quarter. State Street Corp now owns 307,262 shares of the company’s stock worth $1,002,000 after acquiring an additional 93,236 shares during the period. Bank of New York Mellon Corp bought a new position in Cibus during the 2nd quarter worth about $529,000. Finally, Swan Global Investments LLC purchased a new position in Cibus during the 3rd quarter valued at about $115,000. 33.81% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on CBUS. Canaccord Genuity Group raised shares of Cibus to a “strong-buy” rating in a research note on Friday, July 19th. Canaccord Genuity Group restated a “buy” rating and set a $20.00 price objective on shares of Cibus in a report on Tuesday, October 22nd. Alliance Global Partners reduced their target price on Cibus from $25.00 to $23.50 and set a “buy” rating on the stock in a research note on Tuesday, September 24th. Finally, HC Wainwright reiterated a “buy” rating and set a $25.00 target price on shares of Cibus in a research report on Monday, November 11th.

About Cibus

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.